Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)
Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) in a Multi-center, Double-Blinded, Placebo-controlled Trial
Cedars-Sinai Medical Center
80 participants
Apr 20, 2022
INTERVENTIONAL
Summary
Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).
Eligibility
Inclusion Criteria6
- Age greater than or equal to 18 years old, <80 years old
- Chronic Eustachian tube dysfunction defined as:
- Symptoms in one or both ears > 3 months AND
- ETDQ-7 score >14.5 AND
- Type B, C, or As tympanometry
- Female subjects of childbearing potential must have a negative urine pregnancy test at screening and throughout the study duration.
Exclusion Criteria12
- Age <18 years old
- Known history of otologic surgery (excluding myringotomy or myringotomy tubes)
- Use of any additional intranasal medication
- Tympanic membrane perforation
- Adhesive otitis media
- Cholesteatoma or significant retraction pocket
- Middle ear effusion
- Nasopharyngeal tumor
- Any history of head and neck cancer
- Any history of head and neck irradiation
- Any history of temporomandibular disorder or prior surgery to the temporomandibular joint
- Any medical condition that the investigator deems inappropriate for enrollment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05275686